Changes and clinical significance of serum soluble human leukocyte antigen-G and growth differentiation factor 15 in gastric cancer

You-peng YANG,Xiao-lin ZHAO,Fang-hong MU,Gui-bin YANG,Mei-hua CUI,lin YUE
DOI: https://doi.org/10.3969/j.issn.1671-038X.2019.04.09
2019-01-01
Abstract:[Objective]To investigate the changes and clinical significance of serum soluble human leukocyte antigen-G (sHLA-G) and growth differentiation factor-15 (GDF-15) in gastric cancer.[Methods]From January 2015 to December 2017, 88 patients with gastric cancer were selected as gastric cancer group who were divided into stage Ⅰ~Ⅱ group (36 cases) and stage Ⅲ~Ⅳ group (52 cases) according to TNM staging criteria.In addition, 65 patients with gastric disease were selected as gastric disease group and 60 healthy people as control group.The sHLA-G, GDF-15, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125 and alpha-fetoprotein (AFP) levels were measured, and the clinical diagnostic value of sHLA-G and GDF-15 in gastric cancer patients was evaluated by ROC and AUC.[Results]The levels of serum sHLA-G, GDF-15, CEA, CA125 and AFP in gastric cancer group were significantly higher than those of in gastric disease group and control group (P<0.05).The serum sHLA-G, GDF-15, CEA, CA125 and AFP levels in gastric disease group were higher than those of in control group, but there was no significant difference (P>0.05).The serum levels of sHLA-G, GDF-15, CEA, CA125 and AFP in stage Ⅲ and Ⅳ gastric cancer patients were significantly higher than those of in stage Ⅰ and Ⅱ gastric cancer patients (P<0.05).The AUC, sensitivity and specificity of sHLA-G and GDF-15 in diagnosing gastric cancer were better than those of CEA, CA125 and AFP.[Conclusion]sHLA-G and GDF-15 are related to the occurrence and development of gastric cancer, which could be used as an marker for the diagnosis of gastric cancer.
What problem does this paper attempt to address?